Related Experiment Video
Updated: Oct 9, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
Seiji Kobayashi1, Kazunori Fugo2, Kazuto Yamazaki2
1Division of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.
Abstract:
We report on the onset of minimal change disease (MCD) presenting with anasarca after a second dose of the messenger RNA (mRNA)-based Pfizer-BioNTech vaccine against coronavirus disease 2019 (COVID-19). A 75-year-old previously healthy male was admitted with rapidly progressive anasarca and proteinuria of 7.7 g/day following the second dose. A kidney biopsy revealed MCD with nephrotic syndrome. He was treated with intravenous methylprednisolone followed by prednisolone, leading to complete remission after 35 days in the hospital. Since definite causality between the vaccine and MCD remains unclear, awareness of this potential adverse effect of mRNA vaccines is important to determine its true incidence and frequency.
More Related Videos
Related Concept Videos
Vaccinations
Cross-reactivity
FDA Approved Drugs: Changes to Approved Drugs
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Microorganisms in Medicine and Therapeutics
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

